排序方式: 共有20条查询结果,搜索用时 15 毫秒
1.
目的 应用新型杆状病毒表达系统快速构建含有HBsAg基因的重组杆状病毒,高效表达HBsAg,为HBV诊断试剂、疫苗及治疗研究提供依据。方法 构建含有HBsAg基因的供体质粒pFB-BS,转化Bac-to-Bac杆状病毒表达试剂盒中的DH10Bac致敏菌,利用其含有的细菌Tn7转座繁忙将HBsAg基因重组至穿梭质粒Bacmid上,快速筛选出含有HBsAg基因的重组杆状病毒。结果 此重组病毒能在昆虫细 相似文献
2.
腹部术后早期肠内营养支持的临床研究 总被引:3,自引:1,他引:3
为了研究手术后早期胃肠内营养支持的有效性及安全性,我们将腹部手术病人随机分为肠内与肠外营养两组。自术后第一天起给予等氮等热量的营养支持,持续8天。结果发现营养支持前后研究组病人前白蛋白、转铁蛋白水平较对照组明显升高且手术后第二日即达到正氮平衡,无明显的肝肾功能影响,消化道反应轻。认为术后早期营养支持是安全有效的。 相似文献
3.
Notice is hereby given that pursuant to the Board of Directors the annual meeting of members will convene at the Association's Food Nutrition Conference Expo at am on Monday October at McCormick Place West in Chicago IL. Full registration for members is $ if postmarked on or before September or $ after September . 《Journal of the American Dietetic Association》2008,108(9):1558-1559
4.
5.
腰椎间盘突出症的非手术治疗 总被引:4,自引:0,他引:4
近三年来运用药物、牵引、手法推拿、硬膜外腔注射、功能锻炼等治疗方法,对312例腰椎间盘突出症进行了治疗和观察,结果:治愈267例,占85.5%;有效33例,占11%;无效12例,占3.5%。总有效率为96.5%。中西医结合疗效有助于腰椎间盘突出症的症状缓解和恢复,疗效显著。 相似文献
6.
7.
8.
10.
GEORGE H. CROSSLEY M.D. KAZUTAKA AONUMA M.D. † CHARLES HAFFAJEE M.D. ‡ MORIO SHODA M.D. § ALBERT MEIJER M.D. ¶ ALEXANDER BAUER M.D. # GIUSEPPE BORIANI M.D. JESPER SVENDSEN M.D. $ SHELLEY THOMAS R.N. B.S. £ CHRISTOPHER WIGGENHORN Ph .D.£ CHRISTINA UNTERBERG-BUCHWALD M.D. for the Concerto-AT Study Investigators 《Pacing and clinical electrophysiology : PACE》2009,32(1):13-23
Background: Atrial fibrillation (AF) is a major cause of morbidity and mortality, especially in patients with congestive heart failure.
Objectives: The purposes of this international, prospective multicenter study were to evaluate the efficacy of atrial shock therapy in patients with a cardiac resynchronization therapy defibrillator (CRT-D) and to evaluate the safety of the new CRT-D. The effectiveness of a new wireless telemetry system was also evaluated.
Methods: A total of 282 patients, without permanent AF, who had indications for a CRT-D were included. Atrial shock therapy was tested on both spontaneous and induced AF episodes. The effectiveness of the Medtronic wireless telemetry system (Conexus; Medtronic Inc., Minneapolis, MN, USA) was also tested. Secondary endpoints included the heart failure Clinical Composite Response, system performance evaluation, and adverse event summary.
Results: Atrial shock therapy was successful in 168 of 171 episodes (98.2%). Of these, 138 episodes were induced and 33 were spontaneous. Successful cardioversion occurred in 137 of the 138 induced-AF episodes (86.1% with 12 joule (J), 13.1% with 24 J, and 0.7% with 35 J). During the first 3 months of implant, there were 43 system-related complications in 37 subjects out of 278 subjects. There were 1,999 Conexus telemetry uses recorded during this study. This includes 282 uses during the implant procedure. There were no cases of complete loss of telemetry or any adverse events reported using this system.
Conclusion: We achieved an atrial shock efficacy of 98.2% in patients who met standard CRT-D indications. The wireless telemetry performed well with no reported unanticipated adverse device effects. 相似文献
Objectives: The purposes of this international, prospective multicenter study were to evaluate the efficacy of atrial shock therapy in patients with a cardiac resynchronization therapy defibrillator (CRT-D) and to evaluate the safety of the new CRT-D. The effectiveness of a new wireless telemetry system was also evaluated.
Methods: A total of 282 patients, without permanent AF, who had indications for a CRT-D were included. Atrial shock therapy was tested on both spontaneous and induced AF episodes. The effectiveness of the Medtronic wireless telemetry system (Conexus; Medtronic Inc., Minneapolis, MN, USA) was also tested. Secondary endpoints included the heart failure Clinical Composite Response, system performance evaluation, and adverse event summary.
Results: Atrial shock therapy was successful in 168 of 171 episodes (98.2%). Of these, 138 episodes were induced and 33 were spontaneous. Successful cardioversion occurred in 137 of the 138 induced-AF episodes (86.1% with 12 joule (J), 13.1% with 24 J, and 0.7% with 35 J). During the first 3 months of implant, there were 43 system-related complications in 37 subjects out of 278 subjects. There were 1,999 Conexus telemetry uses recorded during this study. This includes 282 uses during the implant procedure. There were no cases of complete loss of telemetry or any adverse events reported using this system.
Conclusion: We achieved an atrial shock efficacy of 98.2% in patients who met standard CRT-D indications. The wireless telemetry performed well with no reported unanticipated adverse device effects. 相似文献